GASTRIC CANCER

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This study tested an experimental drug called SAR443216 in 44 adults with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer) that had stopped responding to other treatments. The goal was to find a safe dose and see if it could shrink tumors. However, the t…

This early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize a specific cancer mutation (KRAS G12D), and then given back to attack tumors. It involved 5 adults with advanced gastrointestinal, pancreatic, gastric,…

This early-stage study tested a new drug called AUR106 in 21 adults with advanced cancers (lung, stomach, bladder, kidney, colon, or esophagus) that had come back or spread. The main goal was to find a safe dose and check how the drug moves through the body. The study was stopped…

This study tested a new drug called BLU-222 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, so results are limited.

This study tested a new drug called TAK-500, alone or with pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited.

This study tested a new way to give chemotherapy for stomach cancer that has spread throughout the belly (peritoneal carcinomatosis). Participants received one chemo drug through a port in the belly and through a vein, plus another chemo drug by mouth. The goal was to see if this…

This study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…

This early-stage study tested a new drug, PF-07265028, alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head & neck cancers. The goal was to find the safest dose and see if the drugs shrink tumors. The study was terminated early…

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This study tested a new drug (DKN-01) combined with an immunotherapy (tislelizumab) and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial aimed to see if the combination was safe and could slow cancer…

This study aimed to find genetic and lifestyle reasons why stomach cancer is more common in some Hispanic people. Researchers compared DNA from cancer tissue and saliva, and asked about diet and exposures. The study was stopped early, but it may help future research.